Physician profile
Nathan D Edwards
NPI 1730408956
$390.64
in general payments reported to CMS, 2019-2025
8 companies · $14.72 in 2025
The $14.72 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.90 · 2021: $50.87 · 2022: $55.00 · 2023: $85.25 · 2024: $89.90 · 2025: $14.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $169.87 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $98.09 | 2019-2024 | Myday Contact Lens |
| Alcon Vision LLC | $83.91 | 2021-2025 | Precision 1 |
| Abbvie INC. | $55.00 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $51.36 | 2021-2023 | Lipiflow System Activator (Disposable), Meibomian Gland Evaluator |
| Carl Zeiss Meditec, INC. | $48.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $40.30 | 2023 | |
| Allergan, INC. | $12.60 | 2021 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.